Switzerland· 66283001
Suliqua 100/50, solution injectable
A insulins and analogues for injection, long-acting product containing insulinum glarginum, lixisenatidum, registered in Switzerland by Sanofi-Aventis (Suisse) SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 5 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Insulinum glarginum, lixisenatidum is registered in 5 of 19 countries.
Countries holding a registration under ATC A10AE (insulins and analogues for injection, long-acting), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 4 of them publish a price we can compare per daily dose
Insulinum glarginum, lixisenatidum · ATC A10AE
5 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Polandprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- insulinum glarginum, lixisenatidum
- Manufacturer
- Sanofi-Aventis (Suisse) SA
- Country
- Switzerland (CH)
- ATC code
- A10AE
- ATC class
- Insulins and analogues for injection, long-acting
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680662830011Fertpen 3 StkCHF 102.65
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulinum glarginum, lixisenatidum in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSULIQUASanofi Winthrop Industrie, Gentilly
- PolandSuliquaSanofi Winthrop Industrie
- SwedenSuliqua 100 enheter/ml+33 mikrogram/ml Injektionsvätska, lösning i förfylld injektionspennaSanofi Winthrop Industrie
- SpainSULIQUA 100 UNIDADES/ML + 33 MICROGRAMOS/ML SOLUCION INYECTABLE EN PLUMA PRECARGADASanofi Winthrop Industrie
- FinlandSuliquaSanofi Winthrop Industrie
- United KingdomSuliqua 100units/ml / 33micrograms/ml solution for injection 3ml pre-filled SoloStar pensSanofi
- IrelandSuliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled penSanofi-Aventis Groupe
- IcelandSuliquaSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Suliqua
- Liechtenstein · Suliqua
- Norway · Suliqua
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf9addab-0f74-4335-96e7-377294bf6eb7 GET /v1/drugs/cf9addab-0f74-4335-96e7-377294bf6eb7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "insulinum glarginum 100 U + lixisenatidum 0.05 mg",
"valid_from": "2018-01-01",
"limitations": "[{\"description\":\"Suliqua wird in Kombination mit Metformin zur Behandlung des Diabetes mellitus Typ 2 bei Erwachsenen angewendet, wenn Metformin allein oder eine Kombinationstherapie mit Metformin und Sulfonylharnstoff, Metformin und einem GLP-1-Rezeptoragonisten oder Metformin und Basalinsulin keine ausreichende Blutzuckereinstellung gewährleistet.<br>\\nMindestens BMI 28. Zusätzliche Medikamente zur Gewichtsreduktion werden nicht vom Krankenversicherer vergütet.<br>\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2018-01-01\"}]",
"galenic_form": "Inj Lös SoloStar",
"therapeutic_area": null,
"sl_inclusion_date": "2018-01-01",
"self_retention_pct": 10
}See everything about insulinum glarginum, lixisenatidum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.